BeOne Medicines Ltd. (ONC): debt financing — BeOne sells IMDELLTRA ex-China royalty rights to Royalty Pharma for up to $950M

BeOne Medicines Ltd.

Upfront payment of $885M; option to sell additional royalties within 12 months for up to $65M.
BeOne retains share of royalty on annual ex-China net sales above $1.5B and all other Amgen collaboration rights.
IMDELLTRA is a DLL3-targeting bispecific T-cell engager approved in US for ES-SCLC after platinum chemo.
Transaction expected to close shortly; proceeds provide operational and strategic flexibility.

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.85

BeOne Medicines Ltd. incurred debt of $885 million upfront payment, with option for up to $65 million additional with Royalty Pharma Investments 2023 ICAV maturing sixty days after the latest of: on a country-by-country basis, (i) the date on which the exploitation of any such Imdelltra Product no longer infringes an appli.

Principal: $885 million upfront payment, with option for up to $65 million additional
Counterparty: Royalty Pharma Investments 2023 ICAV
Maturity: sixty days after the latest of: on a country-by-country basis, (i) the date on which the exploitation of any such Imdelltra Product no longer infringes an appli
Event: incurrence

Exact text from the filing

(the “Company”), BeOne Medicines I GmbH (the “Seller”), a subsidiary of the Company, and Royalty Pharma Investments 2023 ICAV (“Royalty Pharma”) entered into a Royalty Purchase Agreement (the “Royalty Purchase Agreement”).

View on SEC.gov

Browse all debt financings →

BeOne Medicines Ltd. filing history →

Source: SEC EDGAR

accession 0001628280-25-041082

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.